Roche’s Tecentriq to be filed for early-stage liver cancer
pharmaphorum
JANUARY 19, 2023
A regimen of Roche’s Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3 trial, according to the company. Overall, liver cancer is the third leading cause of cancer death.
52 
Let's personalize your content